Patient, industry, and regulatory perspective on antibody-drug conjugates dose optimization

Clin Transl Sci. 2024 Mar;17(3):e13759. doi: 10.1111/cts.13759.

Authors

Salaheldin Hamed¹, Chunze Li², Michael Z Liao², Lorna Warwick³, Zhu Zhou⁴

Affiliations

¹ Astellas Pharma US, Inc., Northbrook, Illinois, USA.
² Genentech Inc., South San Francisco, California, USA.
³ Lymphoma Coalition, Mississauga, Ontario, Canada.
⁴ Department of Chemistry, York College, City University of New York, Jamaica, New York, USA.

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antibodies, Monoclonal
Antineoplastic Agents*
Humans
Immunoconjugates*

Substances

Immunoconjugates
Antineoplastic Agents
Antibodies, Monoclonal

Grants and funding

R16 GM146679/GM/NIGMS NIH HHS/United States